Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma

Abstract

Improvements in the treatment of solid tumors may increase the incidence of tumor lysis syndrome for tumors once believed to be marginally responsive. Oncologists should remain cognizant of this problem as more active regimens become available.